{
    "organizations": [],
    "uuid": "dbbb62ec0dae3f21770c96026ad9794d12001cdf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-voyager-therapeutics-and-abbvie-an/brief-voyager-therapeutics-and-abbvie-announce-global-strategic-collaboration-idUSFWN1QA0FN",
    "ord_in_thread": 0,
    "title": "BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Abbvie Inc:\n* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMERâ€™S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES\n* VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE $69 MILLION UPFRONT PAYMENT AND POTENTIALLY UP TO $155 MILLION IN PRECLINICAL AND PHASE 1 OPTION PAYMENTS\n* VOYAGER THERAPEUTICS - IS ALSO ELIGIBLE TO GET UP TO $895 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES FOR EACH VECTORIZED TAU ANTIBODY COMPOUND Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-20T20:18:00.000+02:00",
    "crawled": "2018-02-21T21:12:56.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "abbvie",
        "inc",
        "voyager",
        "therapeutic",
        "abbvie",
        "announce",
        "global",
        "strategic",
        "collaboration",
        "develop",
        "potential",
        "new",
        "treatment",
        "alzheimer",
        "disease",
        "neurodegenerative",
        "disease",
        "voyager",
        "therapeutic",
        "inc",
        "voyager",
        "receive",
        "million",
        "upfront",
        "payment",
        "potentially",
        "million",
        "preclinical",
        "phase",
        "option",
        "payment",
        "voyager",
        "therapeutic",
        "also",
        "eligible",
        "get",
        "million",
        "development",
        "regulatory",
        "milestone",
        "vectorized",
        "tau",
        "antibody",
        "compound",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}